Healthcare / Medical Instruments & SuppliesTaipei Exchange
$30.50
-0.20 (-0.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $72.5M · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$0
P/E
15.2x
↓EV/EBITDA
6.3x
↓ROE
9.3%
↑Gross Margin
13.9%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.7%
FCF CAGR
+1.5%
FCF margin
12.6%
FCF / Net income
1.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $964.4M · net income $67.4M · FCF $121.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $964.4M | $964.4M | $889.8M | $833.2M | $889.2M |
| Net Income | $67.4M | $67.4M | $49.6M | $42.7M | $50.7M |
| EBITDA | $171.7M | $171.7M | $152.2M | $137.5M | $144.2M |
| EPS | — | — | 1.48 | 1.28 | 1.52 |
| Gross Margin | 13.9% | 13.9% | 12.3% | 12.3% | 12.3% |
| Operating Margin | 7.5% | 7.5% | 6.9% | 6.6% | 7.2% |
| Net Margin | 7.0% | 7.0% | 5.6% | 5.1% | 5.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.30 | 0.32 | 0.29 |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $121.9M | $121.9M | $72.5M | $23.5M | $116.5M |
| Returns | |||||
| ROE | 9.3% | 9.3% | 7.1% | 6.3% | 7.5% |
| Valuation | |||||
| P/E | 15.17 | 15.17 | 17.70 | 20.39 | 15.99 |
| EV/EBITDA | 6.28 | 6.28 | 6.43 | 7.11 | 5.28 |
| P/B | 1.40 | 1.40 | 1.26 | 1.28 | 1.21 |
| Growth & Yield | |||||
| Revenue Growth | 8.4% | 8.4% | 6.8% | -6.3% | — |
| EPS Growth | — | — | 15.6% | -15.8% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.9%
Start / end P/E
n/dx → n/dx
EPS bridge
1.48 → n/d
Residual
+13.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.